Results appear in line with expectations. Interim dividend around AUD$1.46 despite slight profit drop due to anticipated Ig and albumin constrained sales as a result of covid. Seqirus performed well!! FY22 net profit anticipated to be in the range of approximately US$2.15 billion. Outlook sounds bullish!!
Ann: Half Year Results Announcement, page-2
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$288.61 |
Change
1.590(0.55%) |
Mkt cap ! $139.7B | |||
| Open | High | Low | Value | Volume |
| $289.01 | $289.50 | $287.03 | $102.6M | 356.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2 | $288.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $288.79 | 200 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |